Life Science Partner recruits former Director, Worldwide Regulatory Affairs at Boston Scientific

Life Science Partner announces the recruitment of Lisa Becker, a senior medical device regulatory executive, to become Senior Director of Regulatory Affairs for the AGA Medical Corporation.

AGA Medical is a Plymouth, Minnesota based medical device company focused on the development, design, manufacture, and marketing of nitinol-based occlusion devices and accessories for the minimally invasive treatment of cardiovascular defects and peripheral vascular disease. AGA Medical was recently acquired by St. Jude Medical.

In her most recent role at Boston Scientific, Becker served as Director of Worldwide Regulatory Affairs for the Cardiac Rhythm Management Division.  During Becker’s long tenure at Guidant/Boston Scientific, she served in numerous regulatory leadership roles of increasing responsibility for the company.  Becker’s early career was spent in the U.S Air Force as a Military Personnel Flight Commander.

“Lisa is an articulate and passionate leader who has built both small highly efficient regulatory teams and managed large complex international regulatory organizations,” noted Tom Callaway, MD, founder and president of Life Science Partner.  “She has an impressive track record of creating innovative systems which utilize data-driven metrics to accelerate the regulatory approval process.”

Becker earned a Bachelor of Science degree in Organizational Behavior with General Engineering Minor from the United State Air Force Academy and a Master of Science degree in Human Resource Management and Information Systems from Chapman University.

Life Science Partner recruits former President and Chief Executive Officer of Qteros

Life Science Partner announces the recruitment of William  (Bill) Frey, PhD, most recently President and Chief Executive Officer for Qteros, to Georgia Pacific to lead a new business development initiative on disruptive technologies across the company. 

In this role, Frey will be responsible for key areas of investment, such as the use of biotechnology in processing of wood products, materials sciences to create new products, and process engineering to reduce water and energy utilization for a more sustainable business enterprise.

Frey is well qualified to develop this initiative at Georgia Pacific from his leadership at Qteros, a cellulosic ethanol technology company dedicated to accelerating the global commercialization of renewable biofuels.

Previously, Frey served as Global Business Director at DuPont Biofuels where he led global business activities and commercialization of Advanced Biofuels and New Cellulosic Process technologies for the company, resulting in the formation of DuPont Biofuels.   Frey has a significant track record for championing innovation during his 28 years at DuPont, including the creation of new biotechnology-based businesses.

“Frey brings his broad experience and successful insights in identifying and executing transformative opportunities in biofuels and sustainable chemicals and materials to the company,” noted Tom Callaway, President of Life Science Partner.  “His unique blend of developing strategic partners from both sides – large company to small and small company to large – will serve him well in his new role.”

Frey earned his Bachelor of Science Degree in Chemistry from King’s College in Wilkes-Barre, PA.  He received a PhD in Organic Chemical with an Enzymology and Biochemistry focus from Pennsylvania State University.  He completed his Postdoctoral Fellowship at Harvard Medical School.

Life Science Partner recruits former Clinical Affairs Executive at ATS Medical, Inc.

Life Science Partner announces the recruitment of Maria Koullick, PhD, a senior clinical trials executive, to AGA Medical to become Senior Director of Clinical Affairs for the company.

AGA Medical Corporation is a Plymouth, Minnesota based medical device company focused on the development, design, manufacture, and marketing of nitinol-based occlusion devices and accessories for the minimally invasive treatment of cardiovascular defects and peripheral vascular disease.  AGA Medical was recently acquired by St. Jude Medical.

Koullick comes to AGA Medical from ATS Medical, a Minneapolis-based company which was recently acquired by Medtronic.  She directed the strategy and executed the company’s clinical programs for surgical valves, repair products and surgical ablation technologies.

Previously, Koullick held similar roles of increasing responsibility at Medtronic’s Cardiac Rhythm Disease Management and Neurological Divisions.

“Maria has a unique international clinical research trajectory – from the Cardiovascular Surgery Center in Moscow to the National Cardiovascular Surgery Center in Osaka to Medtronic,” noted Tom Callaway, MD, founder and president of Life Science Partner.  “Her metric-driven skills emerge from her PhD in Biomedical Engineering, but she has also demonstrated her ability to build and lead a team that accomplishes difficult goals.

She will serve the company well in its mission to bring lasting improvements for patients with cardiovascular defects and peripheral vascular disease.”

Koullick earned her Bachelor and Master of Science degrees in Organic Chemistry from the University of Chemical Technology in Moscow, Russia.  She completed her PhD in Biomedical Engineering at the Bakulev Cardiovascular Surgery Center.

Life Science Partner recruits former Executive Vice President at inVentiv Clinical Solutions

Life Science Partner announces the recruitment of Scott Treiber, PhD, an experienced clinical research leader, to Hospira to become Vice President of Clinical Operations and Medical Affairs.

Hospira is a $5 B global specialty pharmaceutical and medication delivery company based in Lake Forest, Illinois.

Previously Treiber served as Executive Vice President Clinical Development at inVentiv Clinical Solutions.  He had responsibility for all aspects of clinical monitoring and project management, including executive project oversight and client interaction for full service clinical trials managed by the company.   Earlier Treiber held senior-level positions at leading Contract Research Organizations, including PharmaNet, Quintiles, ICON and Premier Research.

“Treiber has a depth of experience in clinical development organizational management in a wide range of therapeutic categories including neuroscience, cardiovascular, general medicine and oncology,” noted Tom Callaway, MD, President of Life Science Partner.  “His global CRO background will serve the company well as it transforms its business to a more diversified pharmaceutical company including a portfolio of biosimilar drugs.”

Treiber earned his Bachelor of Science Degree in Biology from the University of Iowa and his PhD in Biology from the University of California Santa Cruz.  He completed his MBA from Ellis College, New York Institute of Technology.

Life Science Partner recruits former Vice President, Medical Affairs at McKesson Provider Technologies

Life Science Partner announces the recruitment of Seema Kumbhat, MD to Hospira to become Medical Director, Device Development – Clinical Decision Support.

Hospira is a $5 B global specialty pharmaceutical and medication delivery company based in Lake Forest, Illinois.   In this new role, she will be responsible for the customer-relations and the clinical-insights into Hospira’s increasingly sophisticated drug delivery systems.

Kumbhat comes well prepared for the role, as she has led clinical teams and customer relationships in the leading healthcare IT companies.  As Vice President of Medical Affairs at McKesson Provider Technologies, Kumbhat served as the key clinical liaison across large healthcare systems and physician practices for the company.

Earlier, Kumbhat served as Enterprise Clinical Manager and Physician Consultant for GE Healthcare IT Solutions where she managed a team of content experts in software configuration for specific clinical specifications.  She joined industry directly from her surgical residency program to help EPI Systems develop their surgery, anesthesia and enterprise medical record systems.

“Kumbhat is articulate and passionate about making healthcare IT solutions that serve the physicians and hospital-based caregivers with efficiency and real-world solutions,” noted Tom Callaway, MD, President of Life Science Partner.  “Her broad background as a physician liaison and her direct experience in the field of product development and customer support will be a great asset to the Medical Device team at Hospira”

Kumbhat earned her Bachelor of Science Degree (Magna cum Laude) from the University of Miami and her Medical Degree with Research Distinction in Surgery at the University of Miami School of Medicine.

Former Professor and Vice-Chair of the Department of Pathology and Laboratory Medicine at the University of North Carolina at Chapel Hill and Director of McLendon Clinical Laboratories Joins LabCorp.

Life Science Partner announces the recruitment of Mark Brecher, MD, formerly Director of McLendon Clinical Laboratories at the University of North Carolina Hospitals, to the Laboratory Corporation of America (LabCorp).

LabCorp is one of the world’s largest clinical laboratory networks with scientific expertise in esoteric testing, genomics, and clinical and anatomic pathology.  LabCorp performs more than one million tests on approximately 400,000 samples each day.  LabCorp is a pioneer in the commercialization of new diagnostic technologies, with more than 35 years of experience in serving physicians and their patients. Brecher will fill the role of retiring Chief Medical Officer, Myla Lai-Goldman.

Brecher has been with the University of North Carolina at Chapel Hill since 1992 where he most recently served as Professor and Vice-Chair of the Department of Pathology and Laboratory Medicine, Chair of the McLendon Clinical Laboratories, Director of Clinical Pathology and the past Director of Transplantation and Transfusion Services.

In his new role at LabCorp, Brecher will have primary responsibility to oversee the clinical pathologists and laboratory technicians, lead quality for the organization, and provide insight into new technologies and services that will make LabCorp the continued leader in the clinical diagnostic arena.

“Brecher is a demonstrated leader in academic medicine – and in providing leadership to physician-led organizations,” noted Tom Callaway, President of Life Science Partner.    “While he has a national reputation in transfusion medicine, but he has built a solid program at Chapel Hill of outreach to physicians seeking esoteric testing services.”

Brecher was awarded his Bachelor of Science Degree in Chemistry at Emory University and his Medical Degree from the Pritzker School of Medicine at the University of Chicago.   He completed a Surgical Residency, as well as Clinical and Anatomic Pathology Residencies, at the University of Chicago School of Medicine where he served at Chief Resident.

Life Science Partner recruits former Director of the Biologics Manufacturing Launch Teams at Bristol-Myers Squibb Company

Life Science Partner announces the recruitment of Tom Vanden Boom, PhD, a senior biopharmaceutical executive in the development, manufacturing and commercial launch of biologic products.

Hospira is a global specialty pharmaceutical and medication delivery company that develops, manufactures and markets products that help improve the safety, effectiveness and costs of patient care.

In his most recent role at Bristol-Myers Squibb, Vanden Boom was responsible for leading the Biologics Manufacturing Launch Teams for global technical operations manufacturing and supply chain activities supporting the commercial launch of all new biologic products for the company.   Prior to his tenure at Bristol-Myers Squibb, Vanden Boom served as the Department Head of Biological Development at Abbott Laboratories.  In his new role at Hospira, he will provide strategic and technical leadership for the company’s drive to develop biosimilars drugs for some of the world’s blockbuster biological drugs.

“Vanden Boom is a talented strategic leader with an established track record of building highly successful teams and managing complex biological projects,” noted Tom Callaway, President of Life Science Partner.  “His considerable technical and business expertise in the development of biopharmaceuticals will serve Hospira well in its mission to become a global leader in providing biosimilar versions of the world’s most critical biological drugs.”

Vanden Boom earned a Bachelor of Science degree in Biochemistry and a Masters in Bacteriology from the University of Wisconsin – Madison.  He received his PhD in Microbiology from the University of Illinois at Urbana-Champaign.  There, he also completed a post-doctoral in Molecular Genetics.

Learn More About Life Science Partner

Click button below to learn more about how we recruit Chief Executives:

C

Life Science Partner recruits former Lead Director of Clinical Affairs at Boston Scientific Cardiac Rhythm Management Division.

Life Science Partner announces the recruitment of clinical affairs executive Steve McQuillan to Medtronic’s Cardiac Rhythm Disease Management Division (CRDM), the largest and oldest business unit of the global $13.5 billion medical device company.

With the recent acquisitions of Ablation Frontiers and CryoCath Technologies, the newly formed CRDM Business Unit, AF Solutions, brings breakthrough therapeutic choices and tools to physicians and their patients with atrial fibrillation.

In his most recent role at Boston Scientific Cardiac Rhythm Management (CRM) Division, McQuillan was responsible for developing and implementing the CRM and Electrophysiology clinical strategy for all US-based clinical trials.   He had a steady and successful rise through his tenure at the Guidant CRM organization prior joining Boston Scientific.   In his new role, McQuillan will provide strategic leadership, oversight, and overall management of the regulatory and clinical activities for the new atrial fibrillation division.

“McQuillan is a passionate, highly motivated executive with wide-ranging clinical and regulatory experience in the CRM space” noted Tom Callaway, MD, founder and president of Life Science Partner.  “Along with his strong relationships with Electrophysiology thought-leaders worldwide, he will bring strong clinical development leadership and quality execution to Medtronic’s CRDM Division.”

McQuillan received his Bachelor of Arts Degree in Biometry and Statistics from the University of Minnesota, Twin Cities.

Life Science Partner recruits former Vice President, Clinical and Regulatory Affairs at Uptake Medical

Life Science Partner announces the recruitment of Pam Simons, an experienced medical device clinical and regulatory executive, to AGA Medical to become Senior Director of Clinical Affairs for the company.

AGA Medical Corporation Plymouth, Minnesota based medical device company focused on the development, design, manufacture, and marketing of nitinol-based occlusion devices and accessories for the minimally invasive treatment of cardiovascular defects and peripheral vascular disease.

In Simons’ previous role at Uptake Medical, a Seattle-based company developing non-surgical treatment for emphysema and COPD, she was responsible for worldwide efforts in clinical and regulatory affairs for the company.  Previously, Simons held a similar role at First Circle Medical where she led development and execution of the company’s global clinical development from Phase I to commercialization.

“Simons is a high energy individual with a demonstrated track record of success in development and execution of clinical strategy and regulatory approval for innovation Class II medical devices,” noted Tom Callaway, MD, founder and president of Life Science Partner.  “With her passion and experience, she will serve AGA Medical well in its mission to bring lasting improvements for patients with cardiovascular defects and peripheral vascular disease.”

Simons earned her Bachelor of Science degree in Radiologic Sciences from the University of North Carolina at Chapel Hill.

Life Science Partner recruits biomaterials expert to lead synthetic cartilage product development

Life Science Partner announces the recruitment of Steve Walsh, PhD, a senior biomaterials technology and development expert, to Carticept Medical to become Vice President, Research and Development for the company. 

Carticept Medical is an Atlanta-based medical device company developing novel therapies designed to address the shortcomings of current conservative and surgical treatment options for patients with osteoarthritis or cartilage injuries.

In his previous role at Cyrolife, another Atlanta-based biotechnology company, Walsh was responsible for leading Biomaterials Technologies and Product Development for the company’s implantable biological devices, surgical adhesives and biomaterials for use in cardiac, vascular, general and reconstructive surgery.

Before his tenure at Cyrolife, Walsh served as Manager of the Implantable Device Development Engineering Group at BioControl Technology in Indiana, PA.   In his new role at Carticept, Walsh will have key responsibility for managing R&D efforts for the company’s synthetic cartilage products and the pipeline portfolio of novel therapeutic solutions.

“Walsh is a talented biomaterials scientist with a deep intellect and passion for his work,” noted Tom Callaway, MD, founder and president of Life Science Partner.  “His deep knowledge base and broad development and process abilities will greatly benefit the important clinical and commercial efforts at Carticept.”

Walsh earned his Bachelor of Science in Plastics Engineering at the University of Lowell in Lowell Massachusetts and his Masters and Doctor of Philosophy degrees in Macromolecular Science at Case Western Reserve University in Cleveland, Ohio.